Alexander S R, Honda M
University of Texas Southwestern Medical Center, Department of Pediatrics, Dallas.
Kidney Int Suppl. 1993 Feb;40:S65-74.
This review surveys the dramatic worldwide expansion of the use of continuous peritoneal dialysis as maintenance renal replacement therapy for children with end-stage renal disease that has occurred during the past decade. Before 1982, fewer than 100 pediatric patients had been treated with continuous ambulatory peritoneal dialysis (CAPD), and continuous cycler peritoneal dialysis (CCPD) for children was virtually unknown. By the end of 1989 CAPD/CCPD was accounting for 50% of pediatric dialysis patients (less than 15 years old) in the United States, 65% in Canada, and 75% in Australia/New Zealand. Growth of CAPD/CCPD for children in Europe overall has been less spectacular, but there is wide variability from country to country, with CAPD/CCPD concentrated in eight member countries of the European Dialysis and Transplant Association. Several of these countries (notably the United Kingdom, Israel, the Netherlands and the former Federal Republic of Germany) were treating 46% to 70% of pediatric patients with CAPD/CCPD by the end of 1987. Other European countries such as France and Spain showed little growth of CAPD/CCPD over the decade (10% to 20% of patients treated with CAPD/CCPD). In Japan, CAPD for children has just begun, but because Japanese children are likely to spend longer periods on dialysis awaiting transplantation, information on long-term use of CAPD/CCPD in children may be forthcoming from Japan in the future. No effort is made to compare CAPD/CCPD to hemodialysis as a maintenance therapy for children. The advantages of CAPD/CCPD for the young patient, especially the infant and very young child are noted, and from the past decade of dramatic worldwide growth of CAPD/CCPD in pediatric patients it is inferred that the majority of children, (from 50% to 75%) can be successfully treated with these modalities, at least for the short-term (that is, several years), while awaiting transplantation.
本综述探讨了过去十年间持续腹膜透析作为终末期肾病患儿维持性肾脏替代治疗在全球范围内的显著扩张。1982年前,接受持续非卧床腹膜透析(CAPD)治疗的儿科患者不足100例,儿童持续循环腹膜透析(CCPD)几乎无人知晓。到1989年底,CAPD/CCPD在美国占儿科透析患者(15岁以下)的50%,在加拿大占65%,在澳大利亚/新西兰占75%。欧洲儿童CAPD/CCPD的总体增长不太显著,但各国差异很大,CAPD/CCPD集中在欧洲透析与移植协会的八个成员国。到1987年底,其中几个国家(尤其是英国、以色列、荷兰和前联邦德国)使用CAPD/CCPD治疗的儿科患者比例为46%至70%。法国和西班牙等其他欧洲国家在这十年间CAPD/CCPD增长甚微(接受CAPD/CCPD治疗的患者比例为10%至20%)。在日本,儿童CAPD刚刚起步,但由于日本儿童等待移植时可能需要更长时间接受透析治疗,未来日本可能会提供儿童长期使用CAPD/CCPD的相关信息。本文未对CAPD/CCPD与血液透析作为儿童维持性治疗方法进行比较。文中指出了CAPD/CCPD对年轻患者,尤其是婴儿和幼儿的优势,从过去十年间全球儿科患者中CAPD/CCPD的显著增长可以推断,至少在短期内(即数年),大多数儿童(50%至75%)可以通过这些方式成功治疗,同时等待移植。